Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT05970718
- Locations
- 🇳🇿
New Zealand Clinical Research, Christchurch, New Zealand
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05955508
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇪🇸Clinica Universidad de Navarra - Madrid, Madrid, Spain
🇪🇸University Hospital Doctor Peset, Valencia, Spain
A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05923424
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg Campus, Leuven, Belgium
Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid
- Conditions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT05906706
A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
- Conditions
- Interventions
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 279
- Registration Number
- NCT05831176
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
🇨🇦University Of Alberta, Edmonton, Alberta, Canada
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT05828511
- Locations
- 🇺🇸
Colorado Blood Cancer Institute/SCRI, Denver, Colorado, United States
🇫🇷Hopital Saint Louis, Paris, France
🇫🇷Hopital Pitié Salpetriere APHP, Paris, France
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 950
- Registration Number
- NCT05800015
- Locations
- 🇺🇸
Crosson Cancer Institute, Fullerton, California, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Arizona Clinical Research Center, Tucson, Arizona, United States
A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
- Conditions
- Interventions
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 155413
- Registration Number
- NCT05791695
- Locations
- 🇺🇸
Regeneron Research Site, Tarrytown, New York, United States
A Study of DB-OTO, an Adeno-associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT05788536
- Locations
- 🇺🇸
Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Seattle Children's Hospital dba Seattle Children's Research Institute, Seattle, Washington, United States
🇺🇸The Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, United States
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 850
- Registration Number
- NCT05785767
- Locations
- 🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸Renovatio Clinical, El Paso, Texas, United States
🇹🇭Prince Of Songkla Hospital, Prince Of Songkhla University, Hat-Yai, Songkhla, Thailand